Fiche centre
University of Alabama
Birmingham — United States
Essais liés5clinical trials
VilleBirminghamlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05126277
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| NRTX-1001 | Épilepsie | Phase 3 | NCT05135091 | Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) | RECRUITING |
| Nintedanib | Myopathies | Phase 4 | NCT05799755 | MINT — Myositis Interstitial Lung Disease Nintedanib Trial | COMPLETED |
| ianalumab s.c. q4w | Lupus | Phase 3 | NCT05126277 | SIRIUS-LN — Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| rapcabtagene autoleucel | Lupus | Phase 2 | NCT06581198 | A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) | ACTIVE_NOT_RECRUITING |
| delpacibart zotadirsen | Myopathies | À vérifier | NCT07250737 | Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping | AVAILABLE |